tobevibart
Vir Biotechnology’s Phase 2 Data for Hepatitis D Combo Regimen Highlights Market Potential
Vir Biotechnology; Phase 2; hepatitis D; combination therapy; tobevibart; elebsiran; SOLSTICE trial; undetectable HDV RNA; market potential; ECLIPSE program